Novartis announced results from two clinical trials on the efficacy of Costentyx (secukinumab) for the treatment of plaque psoriasis of the palms, soles, and nails in adult patients. The data were presented at the 23rd World Congress of Dermatology (WCD) in Vancouver, Canada.

In the GESTURE study, 205 patients with moderate-to-severe palmoplantar psoriasis were randomized to receive Costentyx or placebo over a 132-week treatment period. Costentyx 300mg was superior to placebo at Week 16 in achieving clear or almost clear palms and soles, assessed using the Palmoplantar Investigator’s Global Assessment (33.3% vs. 1.5%; P<0.0001).